CD-20 Antibodies in Chronic Lymphocytic Leukemia
0 Views
administrator
07/14/23
The panelists, William G. Wierda, MD, PhD; Thomas J. Kipps, MD, PhD; Richard F. Furman, MD; Alessandra Ferrajoli, MD; Shuo Ma, MD, PhD; and Susan M. O’Brien, MD, explain the mechanisms of action for the CD20 monoclonal antibodies, obinutuzumab, ofatumumab, and rituximab in the treatment of chronic lymphocytic leukemia.
Show more
Facebook Comments
No comments found